The company was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. The company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word ‘Private’ was removed from the name of the company and the certificate of incorporation of the company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, the company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of the company was changed to ‘Emcure Pharmaceuticals Limited’, pursuant to Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.  

Emcure Pharmaceuticals is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It is a research and development (R&D) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across many countries, with a strong presence in India, Europe and Canada. It is led by Promoters with significant experience in the pharmaceutical industry who are supported by a strong professional management team. It is focused towards pharmaceutical products used in chronic (including sub-chronic) therapeutic areas. The company also sells its portfolio of differentiated products internationally in many countries. It has established its international presence by either developing its own front-end distribution capabilities or focusing on alliances with local and multi-national companies that have an established presence in the therapeutic areas of its focus. The company is an R&D driven company and its core strength lies in its ability to research, develop and manufacture inhouse specialty pharmaceutical products for high-growth therapeutic areas, for which there is limited competition and high barriers to entry.

The company has 13 manufacturing facilities across India. Its facilities are capable of producing pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. Further, its ability to manufacture its own APIs and formulations has allowed it to attain a significant degree of vertical integration, allowing it to source products in a cost-effective manner, ensure quality and security of availability of an essential raw material and protect its intellectual property. In particular, it has in-house manufacturing capabilities for most of its specialty products, including complex injectables, iron products, photo-chemistry products, chiral molecules and biotherapeutics.

Business area of the company

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. The company’s core strength and competitive advantage lie in its established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. 

Key awards, accreditations or recognitions

• 2012: Received the Pharmexcil Silver Patent Award for 2011-2012 for commendable contribution in Bulk Drugs / APIs Category.
• 2013: Received the Pharmexcil Silver Patent Award (Bulk Drugs) for 2012-2013 for commendable contribution in developing pharmaceutical patents.
• 2014: Received the Pharmexcil Gold Patent Award for 2013-2014 for commendable contribution in Bulk Drugs / APIs Category.
• 2015: Received the Pharmexcil Silver Patent Award for 2014-2015 for commendable contribution in Bulk Drugs / APIs Category.
• 2016: Received the Best API Patent Award 2014-2015 by Indian Drug Manufacturers’ Association in IDMA Margi Memorial Best Patents Awards.
• 2017: Received the Best Indian API Patents Award 2015-2016 by Indian Drug Manufacturers’ Association in IDMA Margi Memorial Best Patents Awards.
• 2017: Received recognition from the Limca Books of Records for conducting 16,442 haemoglobin detection tests in a single day across 33 centres in India.
• 2017: Received the Best New Introduction of the Year Silver Award by AWACS (21-50 Acute Category) for introducing Sporaz.
• 2017: Received the New Introduction of the Year Silver Award in the AWACS Awards in Marketing Excellence for Ceastra.
• 2018: Received the Best API Patents Award 2016-2017 by Indian Drug Manufacturers’ Association in IDMA Margi Memorial Best Patents Awards.
• 2018: Received the New Introduction of the Year Chronic/Subchronic Gold Award in the AWACS Awards in Marketing Excellence for Emluz.
• 2019: Received the Best Indian Patents Award 2017-2018 by Indian Drug Manufacturers’ Association in IDMA Margi Memorial Best Patents Awards.
• 2019: Received the Brand of the Year Chronic/Subchronic Bronze Award in the AWACS Awards in Marketing Excellence for Orofer XT.
• 2020: Received the Best API Patents Award 2018-2019 by Indian Drug Manufacturers’ Association in IDMA Margi Memorial Best Patents Awards.
• 2020: Received the Platinum Impact Award in the Pronto Consult Consumer Award for Vylda.
• 2021: Received the Golden Impact Award at the Pronto Consult Consumer Awards for Ferium 500 inj.
• 2021: Received the Best International Patent Award 2019-2021 from the Indian Drug Manufacturers’ Association in the IDMA Margi Patel Choksi Memorial Best Patent Awards.
• 2022: Awarded the Silver Impact Award at Pronto Consult Award for Vylda.
• 2022: Awarded the 1st runner up at the AWACS Pharmarack Awards for New Introduction of the Year above 2,000 crores – Chronic for Dydrofem.

Major events and milestones

• 1981: The company was incorporated as Emcure Pharmaceuticals Private Limited.
• 1999: Amalgamation of Lasor Drugs Limited with company.
• 2001: The company was converted from a deemed public company into a public company.
• 2001: Amalgamation of Emcure Laboratories Private Limited, Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiralal Mehta Sales Private Limited with the company.
• 2001: The company’s Subsidiary, Gennova Biopharmaceuticals Limited was incorporated in India.
• 2002: The company received an approval to manufacture ‘S (-) Amlodipine Besilate tablets Asomex – 2.5’ from the Joint Commissioner, Food and Drugs Administration, Pune, Maharashtra, India.
• 2002: The company’s Subsidiary, Zuventus Healthcare Limited, was incorporated in India.
• 2006: The company established a facility at Kurkumbh, Pune, Maharashtra, India.
• 2006: The company commenced operations of injectables facility at Hinjawadi, Pune, Maharashtra, India.
• 2007: Facility established by Subsidiary, Gennova at Hinjawadi, Pune, Maharashtra, India became operational.
• 2007: The company’s Subsidiary, Gennova received an approval from the Central Drugs Standard Control Organisation to start manufacturing ‘Recombinant Tissue Plasminogen Activator (TNK-t-PA)’.
• 2007: The company’s Subsidiary, Emcure Nigeria Limited, was incorporated in Nigeria.
• 2009: The company commenced production of tablets and capsules at facility at Jammu, Jammu and Kashmir, India.
• 2010: The company’s Subsidiary, Emcure Pharmaceuticals Mena FZ-LLC was incorporated in Dubai.
• 2010: The company’s Subsidiary, Emcure Pharmaceuticals South Africa (Pty) Ltd, was incorporated, in South Africa.
• 2011: The company’s Subsidiary, Emcure Brasil Farmaceutica LTDA, was incorporated, in Brazil.
• 2012: The company acquired rights of BICNU.
• 2012: The company’s Subsidiary, Emcure Pharma UK Ltd., was incorporated in the United Kingdom.
• 2014: The company’s Subsidiary, Emcure UK acquired Tillomed Laboratories Limited.
• 2014: The company’s Subsidiary, Emcure Pharma Peru S.A.C., was incorporated in Peru.
• 2014: The company’s Subsidiary, Emcure Pharma Mexico S.A. DE C.V., was incorporated in Mexico.
• 2015: The company entered into Canada through acquisition of Marcan Pharmaceuticals Inc.
• 2014: The company’s Subsidiary, Emcure Pharmaceuticals Pty Ltd., was incorporated in Australia.
• 2015: The company entered into Canada through acquisition of Marcan Pharmaceuticals Inc.
• 2015: The company’s Subsidiary, Emcure Pharmaceuticals Pty Ltd., was incorporated in Australia.
• 2016: The company’s, Subsidiary Emcure UK acquired Laboratorios Tillomed Spain SLU.
• 2017: The company’s Subsidiary, Zuventus, established a manufacturing facility at Bengaluru, Karnataka, India.
• 2017: The company’s Subsidiary, Tillomed Italia S.R.L, was incorporated in Italy.
• 2018: The company received a license to work a factory in relation to the manufacturing facility situated at Sanand, Gujarat, India.
• 2020: The company’s Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile.
• 2021: The company’s Subsidiary, Lazor Pharmaceuticals Limited, was incorporated in Kenya.
• 2021: The company’s Subsidiary, Emcure Pharma Philippines Inc., was incorporated in Philippines.
• 2022: The company’s Subsidiary, Tillomed Malta Ltd, was incorporated in Malta.
• 2023: The company’s Subsidiary, Marcan Pharmaceuticals Inc., acquired Mantra Pharma Inc.